France
LiMM Therapeutics is carving a niche in the biopharmaceutical landscape through its pioneering approach to neuroimmune interactions. Founded in 2018, the company is spearheading innovation by decoding the molecular dialogues between neuronal and innate lymphoid cells in peripheral tissues—a breakthrough that is set to revolutionize the treatment of inflammatory, infectious, and metabolic diseases.
The company's groundbreaking work primarily focuses on creating NRILs (neuronal reprogrammers of innate lymphocytes), positioning them as a first-in-class therapeutic contender. LiMM Therapeutics prides itself on bridging the gap between neural sensing and immunological discoveries, thus offering novel therapeutic pathways.
Headquartered in France, the company received a substantial grant of €2.50M from the European Innovation Council in October 2021, showcasing significant confidence in its potential. With a forte in Biotechnology and Health Care, LiMM Therapeutics presents a compelling investment opportunity for those seeking to be at the forefront of medical innovation.
